Personalized medicine in oncology: Ethical implications for the delivery of healthcare

Personalized Medicine

Volumn 11, Issue 7, 2014, Pages 659-668

  Egalite, Nathalie ^a   Groisman, Iris Jaitovich ^a   Godard, Beatrice ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

cancer; ethical issues; genomics; personalized medicine; research; social medicine

Indexed keywords

CANCER CENTER; ETHICS; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HUMAN; ONCOLOGY; PERSONALIZED MEDICINE; RESOURCE ALLOCATION; REVIEW;

EID: 84909956885     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.14.53     Document Type: Review

References (38)

1. Teng K, Eng C, Hess CA Building an innovative model for personalized healthcare. Clev. Clin. J. Med. 79 (Suppl. 1), S1-S9 (2012).
2. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5 (11), 845-856 (2005).
3. Vigil CE, Griffiths EA, Wang ES, Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Rev. 25 (3), 139-146 (2011).
4. Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu. Rev. Pharmacol. Toxicol. 53 (1), 475-502 (2013).
5. Butts C, Kamel-Reid S, Batist G Benefits, issues, and recommendations for personalized medicine in oncology in Canada. Curr. Oncol. 20 (5), e475-e483 (2013).
6. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363 (4), 301-304 (2010).
7. Mehta S, Shelling A, Muthukaruppan A Predictive and prognostic molecular markers for cancer medicine. Ther. Adv. Med. Oncol. 2 (2), 125-148 (2010).
8. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy 94 (2), 91-100 (2010).
9. Brenner S, Johnson M, Bridgham J Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat. Biotechnol. 18 (6), 630-634 (2000).
10. Roychowdhury S, Iyer MK, Robinson DR Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3 (111), 111ra121 (2011).
11. Nickel GC, Barnholtz-Sloan J, Gould MP Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS ONE 7 (4), e35262 (2012).
12. Marquis-Nicholson R, Aftimos S, Ashton F Pseudotrisomy 13 syndrome: use of homozygosity mapping to target candidate genes. Gene 486 (1-2), 37-40 (2011).
13. Taby R, Issa JP. Cancer epigenetics. CA Cancer J. Clin. 60 (6), 376-392 (2010).
14. Elena JW, Travis LB, Simonds NI Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J. Natl Cancer Inst. 105 (2), 85-94 (2013).
15. Green RC, Berg JS, Grody WW ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15 (7), 565-574 (2013).
16. Callier SL, Toma I, McCaffrey T, Harralson AF, O'Brien TJ. Engaging the next generation of healthcare professionals in genomics: planning for the future. Pers. Med. 11 (1), 89-98 (2014).
17. Letarte N, Lavoie A, Sheehan N La pharmacothrapie personnalis̈e et la pharmacogńtique. Pharmactuel 46 (4), 258-268 (2013).
18. Ciardiello F, Arnold D, Casali PG Delivering precision medicine in oncology today and in future the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann. Oncol. 25 (9), 1673-1678 (2014).
19. Hiraki S, Rinella E, Schnabel F, Oratz R, Ostrer H. Cancer risk assessment using genetic panel testing: considerations for clinical application. J. Genet. Counsel. 23 (4), 604-617 (2014).
20. Tabor HK, Stock J, Brazg T Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. Am. J. Med. Genet. A 158A (6), 1310-1319 (2012).
21. Machini K, Douglas J, Braxton A, Tsipis J, Kramer K. Genetic counselors views and experiences with the clinical integration of genome sequencing. J. Genet. Counsel. 23 (4), 496-505 (2014).
22. McGowan ML, Settersten RA Jr, Juengst ET, Fishman JR. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine. Urol. Oncol. 32 (2), 187-192 (2014).
23. Fleck LM. Just caring: assessing the ethical and economic costs of personalized medicine. Urol. Oncol. 32 (2), 202-206 (2014).
24. McClellan KA, Avard D, Simard J, Knoppers BM. Personalized medicine and access to health care: potential for inequitable access[quest]. Eur. J. Hum. Genet. 21 (2), 143-147 (2013).
25. American College of Medical Genetics Board of Directors. ACMG policy statement: points to consider in the clinical application of genomic sequencing. Genet. Med. 14, 759-761 (2012).
26. Buckmaster AM, Gallagher P. Experiences of and perspectives on genetic testing for breast/ovarian cancer in and outside of the customary clinical setting. Psychol. Health 25 (9), 1041-1059 (2010).
27. Institute of Medicine. Committee on Psychosocial Services to Cancer Patients/Families in a Community Setting. In: Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs. Adler NE, Ann EK (Eds.) National Academies Press, DC, USA, 51-79 (2008).
28. Willis L, Graham TA, Alarćn T, Alison MR, Tomlinson IPM, Page KM. What can be learnt about disease progression in breast cancer dormancy from relapse data? PLoS ONE 8 (5), e62320 (2013).
29. Baker A-M, Graham TA, Wright NA. Pre-tumour clones, periodic selection and clonal interference in the origin and progression of gastrointestinal cancer: potential for biomarker development. J. Pathol. 229 (4), 502-514 (2013).
30. Aktipis CA, Boddy AM, Gatenby RA, Brown JS, Maley CC. Life history trade-offs in cancer evolution. Nat. Rev. Cancer 13 (12), 883-892 (2013).
31. Juengst ET, Settersten RA Jr, Fishman JR, McGowan ML. After the revolution? Ethical and social challenges in personalized genomic medicine. Pers. Med. 9 (4), 429-439 (2012).
32. Fleck LM. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices. Nat. Biotechnol. 29 (6), 757-768 (2012).
33. Fleck LM. Just Caring: Health Care Rationing and Democratic Deliberation. Oxford University Press, NY, USA (2009).
34. Callahan D. What Kind of Life?: The Limits of Medical Progress. Simon and Schuster, NY, USA (1990).
35. Kurian AW. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr. Opin. Obstet. Gynecol. 22 (1), 72-78 (2010).
36. Burke W, Brown Trinidad S, Press NA. Essential elements of personalized medicine. Urol. Oncol. 32 (2), 193-197 (2014).
37. Schleidgen S, Marckmann G. Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system. BMC Med. Ethics 14, 20 (2013).
38. Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int. J. Cancer 134 (6), 1257-1269 (2014).